HAE · Haemonetics Corporation · Stock research

Current Thesis

The binary flagged in the last note resolved in the operators' favour. On 2026-08-06 Haemonetics reported Q1 FY2027 (quarter ended 2026-06-27) revenue of $339.4M, +5.6% reported and +5.9% organic, against consensus of $327.89M, with adjusted EPS $1.14 versus $1.08 expected and GAAP diluted EPS $0.72. The line the bear case rested on turned: Interventional Technologies printed $59.9M, +2.5% reported and +2.8% organic, after −10.3% organic in Q4 FY2026. Management then raised FY2027 reported revenue growth to +5–8% from +4–7% and organic to +4–7% from +3–6%, with the dollar range moved to $1.401B–$1.441B from $1.410B–$1.427B. Six desks repriced within 48 hours. Price made a new 52-week high of $91.34 and closed $90.80 on 2026-08-14, 0.6% under that high, up 61.3% over three months with RSI(14) at 73.8.

That changes what is on offer. Through June and July the leg was "plasma re-acceleration and a hospital turn are underappreciated." As of 2026-08-06 both are reported facts inside a raised guide, the sell-side carries 8 buy / 3 hold / 0 sell, and the next company-scheduled event is roughly eleven weeks out. The narrative is maturing — the narrative still works (new high after the print) but the controversy that paid for it was settled on a single dated release, and the repricing was compressed into 2026-08-06/07.

Bullish and bearish views on Haemonetics Corporation

The model's bull view on Haemonetics Corporation (HAE), in brief: The disputed segment inflected. Interventional Technologies +2.8% organic in Q1 FY2027 versus −10.3% organic in Q4 FY2026 and −9% for FY2026. CEO Christopher Simon's 2026-05-07 claim that the headwinds were "lapped or reduced" got its first test and passed. Plasma kept… The bear view: The beat was revenue-led; margin stood still. Both cases follow in full.

Bull Case

• The disputed segment inflected. Interventional Technologies +2.8% organic in Q1 FY2027 versus −10.3% organic in Q4 FY2026 and −9% for FY2026. CEO Christopher Simon's 2026-05-07 claim that the headwinds were "lapped or reduced" got its first test and passed.
• Plasma kept compounding under the new segment wrapper. Plasma revenue $155.5M, +7.2% reported / +8.2% organic, inside Apheresis of $191.3M (+6.0% organic), with the Persona PLUS rollout cited on the 2026-08-06 call.
• MedSurg carried its own weight: $148.1M, +6.0% reported / +5.9% organic, with Blood Management Technologies at $88.1M, +8.1% organic.
• Guidance moved up on both ends the same day, which is the estimate support the late-July advance had been running ahead of: reported +5–8%, organic +4–7%, Apheresis FY2027 outlook lifted to low-to-mid-single-digit growth.
• Deleveraging is visible in the filing. Q1 operating cash flow $52M; cash $223.4M against total debt $1,174.2M and net debt $950.8M; management cited $100M of debt repayment during and after the quarter. $325.0M of buyback authorisation remains through April 2028, after 3.0M shares repurchased for $175.0M in FY2026.
• Clinical data landed three days before the print: a 1,623-patient retrospective Emory cohort published 2026-08-03 showed VASCADE MVP XL at 92.5% same-day discharge, 1.2% overall vascular complications and median hemostasis of two minutes.
• Targets moved above spot at most desks: Raymond James to $105 from $90, BTIG to $96, Baird to $96 from $88, Barrington to $95 from $89 (2026-08-06/07).

Bear Case

• The beat was revenue-led; margin stood still. Gross margin 59.8%, flat year over year. Adjusted operating margin 16.9%, up only 10bps — against an FY2027 guide of +50–100bps. Adjusted EPS grew 3.6% while revenue grew 5.6%.
• GAAP profit went backwards: net income $33.0M, −3.0% YoY, on operating income of $57.5M (+6.7%).
• Cash conversion started the year below plan: free cash flow conversion 75% of adjusted net income in Q1 versus a ~80% FY2027 target and 89% delivered in FY2026.
• The guide widened as well as rose. The bottom of the FY2027 revenue range fell to $1.401B from $1.410B while the top went to $1.441B — a wider band around a consensus that sat at roughly $1.402B.
• Blood Center is still shrinking inside Apheresis: Other Apheresis $35.8M, −2.4%, and it is guided to a mid-single-digit FY2027 decline. Reported Apheresis growth will keep reading below the plasma line that drove the re-rate.
• Two of the desks closest to the print stayed on the sidelines, with Citi at Neutral/$92 (from $79) and JP Morgan at Neutral/$86 (2026-08-07) — the latter below the 2026-08-14 close of $90.80.
• Roughly 2 points of FY2027 reported growth come from a 53rd week, so reported and organic diverge all year and the reported line flatters the comparison.

Setup & Price Structure

• Reference close $90.80 (2026-08-14); 52-week high $91.34, 0.6% above the close. The prior high of $87.32 (as of 2026-07-31) was taken out after the print, so the structure is intact and extended at the same time.
• Three-month return +61.3%; RSI(14) 73.8. The pre-print reference close was $85.54 on 2026-07-31, above a 50-day average of $74.52 and a 200-day of $67.63 on that date.
• The relevant shelf is the pre-earnings zone: price traded $77.40–$78.78 on 2026-07-21/22, broke out on 2026-07-28/29 on 802,209 and 893,393 shares, then closed $85.54 into the print. A move back under the print reaction returns price to that congestion.
• Crowding observables, stated as observables: six price-target raises inside 48 hours of the 2026-08-06 release; zero sell ratings across 11 covering analysts; short interest 2.70M shares, 6.03% of float as of 2026-07-31; seven directors each received 2,538 RSUs on 2026-07-24 (annual board grant) and no open-market insider sales surfaced in Form 4 filings around the print; no equity issuance — the capital action running is repurchase, with $325.0M authorised through April 2028.
• No dated company catalyst inside the next 30 days. The gap between a resolved print and the next one is where a crowded post-earnings tape has nothing to absorb supply.

Catalyst Calendar (next 30 days)

• No scheduled company event identified between 2026-08-16 and 2026-09-15. The Q1 print (2026-08-06) and the Q1 FY2027 10-Q (filed 2026-08-06) are both behind.
• Undated, under FDA review: PerQseal Elite. FY2027 guidance assumes zero revenue from it, so clearance is incremental to the raised plan.
• ~2026-10-06 (est.): the 90-day downside catalyst watch Citi opened 2026-07-08 runs out. Citi raised its target to $92 on 2026-08-07 while holding Neutral.
• ~2026-11-05 (est.): Q2 FY2027 results — the first quarter that has to hold the Interventional Technologies turn and show margin moving toward the +50–100bps FY guide.

Elapsed catalysts

• Open-ended, opened 2025-09-26: Commerce Section 232 investigation into imported medical devices, equipment and consumables. Tariffs are already an FY2027 margin assumption; a determination can land inside the window. (passed 334d ago)

What Would Change Our Mind

The structural break is a second quarter of MedSurg growth without margin: adjusted operating margin at or below 16.9% again, with free cash flow conversion still tracking under the ~80% FY2027 target, would say the raised revenue guide is being bought with spend rather than operating leverage. The clean, gradeable version of that break is a weekly close below $85, which surrenders the entire 2026-08-06 print reaction and puts price back into the pre-earnings $77–$85 congestion, with the 50-day (rising, $74.52 as of 2026-07-31) underneath. A second condition sits at the Q2 print: Interventional Technologies back to negative organic growth, or the +4–7% organic FY range left untouched after a soft quarter, would remove the estimate support that arrived on 2026-08-06. Finally, if the theme flips to saturated — coverage saturated at zero sell ratings with price above the median published target and no new operating datapoint — the remaining bid is multiple, and multiple is what the medtech group takes back first.

Correlation Notes

• Beta 0.52 (as of 2026-07-31). HAE trades as defensive medtech with an idiosyncratic plasma driver; it is not a proxy for the AI-capex complex and does not need index beta to work.
• Group context matters for the multiple leg: medtech ran a −8.3% median YTD return through Q2 2026 against +14.1% for the S&P 500 that quarter, and BofA's 2026-07-29 raise to $93 explicitly cited "higher peer valuations." A renewed group de-rate hits the part of this move that came from comparables.
• Plasma volumes correlate with fractionator collection budgets — the CSL relationship already cost a reported revenue step, and organic ex-CSL was the metric that carried FY2026.
• Section 232 device tariffs are a sector-wide input, not a name-specific one; any determination re-rates the whole imported-device cost base at once.